Patents by Inventor Rohan Baker

Rohan Baker has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Publication number: 20230212685
    Abstract: Disclosed herein is a combination of genomic sequences whose methylation patterns have utility for the improved detection and differentiation between colorectal neoplasms. Further disclosed herein are methods, nucleic acids and kits for detecting or differentiating between colorectal neoplasms.
    Type: Application
    Filed: October 31, 2022
    Publication date: July 6, 2023
    Applicants: Quest Diagnostics Investments LLC, Clinical Genomics PTY Ltd
    Inventors: Susanne PEDERSEN, Lawrence LaPOINTE, Rohan BAKER, Amber C. DONAHUE, Yen-lin PENG, Frederic WALDMAN
  • Patent number: 11486007
    Abstract: Disclosed herein is a combination of genomic sequences whose methylation patterns have utility for the improved detection and differentiation between colorectal neoplasms. Further disclosed herein are methods, nucleic acids and kits for detecting or differentiating between colorectal neoplasms.
    Type: Grant
    Filed: June 3, 2015
    Date of Patent: November 1, 2022
    Assignees: Quest Diagnostics Investments Incorporated, CLINICAL GENOMICS PTY LTD
    Inventors: Susanne Pedersen, Lawrence LaPointe, Rohan Baker, Amber C. Donahue, Yen-lin Peng, Frederic Waldman
  • Patent number: 10941449
    Abstract: The present invention relates generally to a method of determining one or more probabilities of respective classifications of a neoplasm into one or more neoplastic categories. More particularly, the present invention relates to a method of determining the probability of classification of a large intestine neoplasm into one or more categories selected from adenoma, stage I, stage II, stage III or stage IV by screening for changes to the methylation levels of a panel of gene markers, including BCAT1, IKZF1, IRF4, GRASP and/or CAHM. The method of the present invention is useful in a range of applications including, but not limited to, those relating to the diagnosis and/or monitoring of colorectal neoplasms, such as colorectal adenocarcinosis.
    Type: Grant
    Filed: May 17, 2013
    Date of Patent: March 9, 2021
    Assignee: CLINICAL GENOMICS PTY. LTD.
    Inventors: Lawrence Charles Lapointe, Susanne K. Pedersen, Rohan Baker, Snigdha Gaur, Melissa Thomas
  • Patent number: 10590468
    Abstract: The present invention relates generally to a method for assessing nucleic acid methylation, in particular DNA and RNA methylation. More particularly, the present invention relates to a method of either qualitatively or quantitatively assessing, with improved sensitivity, the cytosine methylation of partially methylated DNA or RNA. The method of the present invention is useful in a range of applications including, but not limited to, the diagnosis of conditions or monitoring of developmental phenotypes which are characterised by DNA or RNA methylation changes.
    Type: Grant
    Filed: June 1, 2015
    Date of Patent: March 17, 2020
    Assignee: CLINICAL GENOMICS PTY LTD
    Inventors: Susanne Pedersen, Rohan Baker
  • Patent number: 9765397
    Abstract: The present invention relates to a method of screening for the presence of methylated DNA in a biological sample by using multiple methylation-sensitive restriction endonucleases. More particularly, the present invention relates to a method of quantitatively screening for the level of one or more methylated genes of interest without the requirement that an undigested internal reference sample is used as a point of reference against which relative quantification is calculated. The present invention is useful in a range of applications including, but not limited to, providing a simpler and more accurate means to determine DNA methylation status, such as in the context of diagnosing or monitoring conditions characterised by changes to DNA methylation.
    Type: Grant
    Filed: November 26, 2013
    Date of Patent: September 19, 2017
    Assignee: Clinical Genomics Pty Ltd
    Inventors: Aidan McEvoy, Susanne Pedersen, Rohan Baker
  • Publication number: 20170191135
    Abstract: Disclosed herein is a combination of genomic sequences whose methylation patterns have utility for the improved detection and differentiation between colorectal neoplasms. Further disclosed herein are methods, nucleic acids and kits for detecting or differentiating between colorectal neoplasms.
    Type: Application
    Filed: June 3, 2015
    Publication date: July 6, 2017
    Applicants: Quest Diagnostics Investments Incorporated, CLINICAL GENOMICS PTY LTD
    Inventors: Susanne Pedersen, Lawrence LaPointe, Rohan Baker, Amber C. Donahue, Yen-lin Peng, Frederic Waldman
  • Publication number: 20170145485
    Abstract: The present invention relates generally to a method for assessing nucleic acid methylation, in particular DNA and methylation. More particularly, the present invention relates to a method of either qualitatively or quantitatively assessing, with improved sensitivity, the cytosine methylation of partially methylated DNA or RNA. The method of the present invention is useful in a range of applications including, but not limited to, the diagnosis of conditions or monitoring of developmental phenotypes which are characterised by DNA or RNA methylation changes.
    Type: Application
    Filed: June 1, 2015
    Publication date: May 25, 2017
    Applicant: CLINICAL GENOMICS PTY LTD
    Inventors: Susanne PEDERSEN, Rohan BAKER
  • Publication number: 20160017418
    Abstract: The present invention relates to a method of screening for the presence of methylated DNA in a biological sample by using multiple methylation-sensitive restriction endonucleases. More particularly, the present invention relates to a method of quantitatively screening for the level of one or more methylated genes of interest without the requirement that an undigested internal reference sample is used as a point of reference against which relative quantification is calculated. The present invention is useful in a range of applications including, but not limited to, providing a simpler and more accurate means to determine DNA methylation status, such as in the context of diagnosing or monitoring conditions characterised by changes to DNA methylation.
    Type: Application
    Filed: November 26, 2013
    Publication date: January 21, 2016
    Inventors: Aidan MCEVOY, Susanne PEDERSEN, Rohan BAKER
  • Publication number: 20150152505
    Abstract: The present invention relates generally to a method of determining one or more probabilities of respective classifications of a neoplasm into one or more neoplastic categories. More particularly, the present invention relates to a method of determining the probability of classification of a large intestine neoplasm into one or more categories selected from adenoma, stage I, stage II, stage III or stage IV by screening for changes to the methylation levels of a panel of gene markers, including BCAT1, IKZF1, IRF4, GRASP and/or CAHM. The method of the present invention is useful in a range of applications including, but not limited to, those relating to the diagnosis and/or monitoring of colorectal neoplasms, such as colorectal adenocarcinosis.
    Type: Application
    Filed: May 17, 2013
    Publication date: June 4, 2015
    Applicant: CLINICAL GENOMICS PTY. LTD.
    Inventors: Lawrence Charles Lapointe, Susanne K. Pedersen, Rohan Baker, Snigdha Gaur, Melissa Thomas